Seattle Genetics/Takeda's Adcetris to treat Hodgkin's lymphoma, cancer of the lymph nodes, will continue to lead the market in the United States, opines an analyst with research and consulting firm GlobalData.
According to Stelios Tzellos, Ph.D., GlobalData's Analyst covering Oncology and Hematology, the medicine is likely to gain swift popularity following its anticipated label extension in Europe from early 2016.
Tzellos says the therapy was lauded at the recent 2015 American Society of Hematology (ASH) Meeting and Exposition held in Orlando, Florida.
Meanwhile, Bristol-Myers Squibb (BMS) and Merck and Co., will race to bring their anti-PD-1 therapies to the Hodgkin's lymphoma arena. The two major pharmaceutical companies presented clinical trial data at ASH. Also, BMS's Opdivo is slightly better than Merck's Keytruda in terms of clinical efficacy.
"Although Adcetris will surely gain dominance in its field due to its ability to induce durable remission and long-term survival in heavily pre-treated relapsed and refractory Hodgkin's lymphoma patients, Seattle Genetics is taking steps to fend off competition from the two oncology juggernauts. For example, the company is collaborating with BMS to investigate the combination of Adcetris and Opdivo in the salvage setting of relapsed and refractory Hodgkin's lymphoma patients who fail standard front-line chemotherapy. With Seattle Genetics also evaluating the combination of Adcetris with Treanda in the same setting, GlobalData believes the company has chosen a successful strategy to stay ahead in the Hodgkin's lymphoma treatment space," Tzellos adds.